Titanium Heart Triumph: 100 Days of Hope and Innovation

Quick Smiles:

• A man in Australia lived for 100 days with a titanium artificial heart.
• This breakthrough offers new hope for patients waiting for heart transplants.
• The BiVACOR team celebrates a major milestone in heart failure treatment.

In a remarkable medical feat, a man in Australia sustained life for 100 days with a titanium artificial heart while awaiting a donor heart. This achievement marks the longest duration a person has been kept alive using such a device, sparking optimism among its developers for future applications.

Five months ago, a man in his forties, suffering from heart failure, received the BiVACOR Total Artificial Heart (TAH). Unlike traditional devices, the TAH operates without pumps, valves, or other moving parts that could wear out. Instead, it uses magnetic levitation to propel a single rotor, efficiently pumping blood through both ventricles.

Remarkably, the patient was discharged from the hospital before a suitable donor heart was found and successfully transplanted.

In a joint statement, BiVACOR, St. Vincent’s Hospital, and Monash University highlighted the potential of the artificial heart to serve as a long-term solution for individuals with heart failure. “The entire BiVACOR team is deeply grateful to the patient and his family for placing their trust in our Total Artificial Heart,” expressed Daniel Timms, BiVACOR’s founder and the inventor of the device.

Their courage, he noted, “will pave the way for countless more patients to receive this lifesaving technology.”

In the United States, the demand for donor hearts remains high, with approximately 3,500 available annually for over 4,400 individuals joining the waiting list.

The TAH has undergone testing in an early feasibility study aiming for eventual FDA approval. Reports indicate that five patients have received the device, starting with a 58-year-old man at Texas Medical Center last July.

All patients successfully received the implant, with plans to expand the trial to 15 individuals, offering new hope for those battling end-stage heart failure.

Source